Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

by @JTC_PALIdev | Mar 14, 2025 | Press Releases

Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts support safety and tolerability of PALI-2108 No serious adverse events (SAEs) and no treatment-emergent adverse events (TEAEs)...

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

by @JTC_PALIdev | Mar 12, 2025 | Press Releases

PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Abstract was Rated in the Top 10% of all AGA Abstracts Selected for Poster Presentation at DDW Carlsbad, CA, March 12, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade...

Palisade Bio Participates in Virtual Investor “What This Means” Segment

by @JTC_PALIdev | Mar 4, 2025 | Press Releases

Dr. Joerg Heyer, Head of Translational Science and Medicine of Palisade Bio highlights preclinical data for lead product candidate, PALI-2108, for the treatment of Ulcerative Colitis (UC) Carlsbad, CA, March 04, 2025 — Palisade Bio, Inc. (Nasdaq: PALI)...

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

by @JTC_PALIdev | Feb 20, 2025 | Press Releases

Company through its co-development partner, Giiant Pharma, Inc. (“Giiant”), receives funding from Canadian Scientific Research and Experimental Development (SR&ED) Tax Credit Program for PALI-2108 Ongoing progress of Palisade Bio’s Phase 1a/b UC...

Palisade Bio, Inc. Participates in the Virtual Investor “Top 5 for ’25” On-Demand Conference

by @JTC_PALIdev | Feb 19, 2025 | Press Releases

On-demand video webcast now available here Carlsbad, CA, Feb. 19, 2025 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company focused on developing and...